![Richard J. Turner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard J. Turner
Geen lopende functies
Profiel
Richard J.
Turner was the founder of Catalyst Venture Partners Ltd., where he held the title of Managing Director from 1999 to 2011.
Catalyst Venture Partners Ltd.
was founded in 1999.
Mr. Turner's former job was as Director at Transcriptogen Ltd.
from 2013 to 2017.
Eerdere bekende functies van Richard J. Turner
Bedrijven | Functie | Einde |
---|---|---|
Transcriptogen Ltd.
![]() Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Algemeen Directeur | 17-06-2017 |
Catalyst Venture Partners Ltd.
![]() Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Catalyst Venture Partners Ltd.
![]() Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Finance |
Transcriptogen Ltd.
![]() Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Health Technology |